The Center for Rheumatic Disease, Allergy, & Immunology Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2004
NCT00417430
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Alternative names

The Center for Rheumatic Disease, Allergy, and Immunology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

IgG Deficiency (Phase 2)

Infections (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3